Caris Life Sciences (CAI) Accounts Payables (2024 - 2026)

Caris Life Sciences' Accounts Payables history runs 3 years deep, the most recent figure standing at $69.8 million for Q1 2026.

• On a quarterly basis, Accounts Payables changed N/A year-over-year to $69.8 million in Q1 2026; TTM through Mar 2026 was $69.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $39.2 million, up 41.07% from the prior year.
• Accounts Payables improved to $69.8 million in Q1 2026 per CAI's latest filing, from $39.2 million in the prior quarter.
• Across five years, Accounts Payables topped out at $69.8 million in Q1 2026 and bottomed at $27.8 million in Q4 2024.
• The 3-year median for Accounts Payables is $29.0 million (2025), against an average of $38.9 million.
• Biggest YoY gain for Accounts Payables was 41.07% in 2025; the steepest drop was 41.07% in 2025.
• Year by year, Accounts Payables stood at $27.8 million in 2024, then surged by 41.07% to $39.2 million in 2025, then surged by 78.04% to $69.8 million in 2026.
• Per Business Quant, the three latest CAI Accounts Payables figures stand at $69.8 million (Q1 2026), $39.2 million (Q4 2025), and $29.0 million (Q3 2025).